{"organizations": [], "uuid": "a18afe91c8895d1ee49b22ae1decc0621fb68c2d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "//sc.cnbcfm.com/applications/cnbc.com/staticcontent/img/cnbc_logo.gif", "site_section": "http://www.cnbc.com/id/10000027/page/3", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/01/03/globe-newswire-inspiremd-schedules-conference-call-to-discuss-recent-developments-preliminary-sales-results-and-proposals-for-upcoming.html", "country": "US", "domain_rank": 767, "title": "InspireMD Schedules Conference Call to Discuss Recent Developments, Preliminary Sales Results and Proposals for Upcoming Shareholder Meeting", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.019, "site_type": "news", "published": "2018-01-04T00:05:00.000+02:00", "replies_count": 0, "uuid": "a18afe91c8895d1ee49b22ae1decc0621fb68c2d"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/01/03/globe-newswire-inspiremd-schedules-conference-call-to-discuss-recent-developments-preliminary-sales-results-and-proposals-for-upcoming.html", "ord_in_thread": 0, "title": "InspireMD Schedules Conference Call to Discuss Recent Developments, Preliminary Sales Results and Proposals for Upcoming Shareholder Meeting", "locations": [], "entities": {"persons": [], "locations": [{"name": "israel", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "nyse", "sentiment": "neutral"}]}, "highlightText": "", "language": "english", "persons": [], "text": "TEL AVIV, ISRAEL, Jan. 03, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it will host a conference call on Wednesday, January 10th at 10:00 a.m. Eastern Time to discuss recent developments, preliminary unaudited fourth quarter 2017 sales results, and proposals under consideration for the upcoming shareholder meeting. A link to the Company’s definitive proxy statement is available at: https://www.sec.gov/Archives/edgar/data/1433607/000149315217015034/def14a.htm .\nThe conference call will be available via telephone by dialing toll free 877-407-0782 for U.S. callers or +1 201-689-8567 for international callers, or on the Company’s Investor Relations section of the website: http://www.inspiremd.com/en/investors/investor-relations/ .\nA webcast will also be archived on the Company’s website and a telephone replay of the call will be available approximately one hour following the call, through midnight January 24, 2018, and can be accessed by dialing 877-481-4010 for U.S. callers or +1 919-882-2331 for international callers and entering conference ID: 23561.\nAbout InspireMD, Inc.\nInspireMD seeks to utilize its proprietary MicroNet™ technology to make its products the industry standard for embolic protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events.\nInspireMD intends to pursue applications of this MicroNet technology in coronary, carotid (CGuard™), neurovascular, and peripheral artery procedures. InspireMD's common stock is Quote: d on the NYSE American under the ticker symbol NSPR and certain warrants are Quote: d on the NYSE American under the ticker symbol NSPR.WS.\nInvestor Contacts: InspireMD, Inc. Craig Shore Chief Financial Officer Phone: 1-888-776-6804 Email: craigs@inspiremd.com Crescendo Communications, LLC David Waldman Phone: (212) 671-1021 Email: NSPR@crescendo-ir.com\nSource:InspireMD, Inc.", "external_links": ["http://www.inspiremd.com/en/investors/investor-relations/", "https://www.globenewswire.com/Tracker?data=5o9ujr7fZ1yift-SD6oy2OLNpYwjJ87c_geYDV7nTVKNlYbBTpw8htgGMCqOqzDHGMERS_WnPqvhdC5DGP4rHlB9bJqc93I2wyDlJP5fhAU1T-MGx7S_oXK8eTz7cVV--60-qErE31jCb1ZGWKXp1b19e5HbDCplngyHIPJgvsDKah5NPcJ6kHv056TCL9bP", "https://www.globenewswire.com/NewsRoom/AttachmentNg/bd26f8ab-01c6-447f-a581-6d2e5d706f08", "https://www.globenewswire.com/Tracker?data=6_Un77Ixocxx3HN6WihocW9X1O9wKYKtUd_sQ9Nq4AUtAJxLL6dazVPH_qnw2tuCBzljTKuDCj6C6yDtd8shvrzMANCzIXOVMQpWIdKVdJmzjchvhZx1D9hifRcVj9TQHCAiM-i1ZbhATWRyFeY-fnZQmf_i6xlDHpaH1VLPDj6rl553S-lg-q_72FYmRfl3keUslZBrNuQ7_A9WooL-byumXBECYiDbKOrUSX4S0eY=", "https://www.sec.gov/Archives/edgar/data/1433607/000149315217015034/def14a.htm", "https://www.globenewswire.com/Tracker?data=qh5_9yYcPS7oVS1CGCvyJQ1Qyw44k4XRaL3PczMHTd2oOVsTUrDwakfgPi8DfTEesv8x3v1tkkSiAhFcQuJcVw=="], "published": "2018-01-04T00:05:00.000+02:00", "crawled": "2018-01-04T00:34:03.001+02:00", "highlightTitle": ""}